Khan S, Chang SH, Hicks V, et al. - Progression to lethal prostate cancer (PCa) in men with advanced PCa could be averted by post diagnostic metformin and statin use.

• From the Veteran Health Administration, a total of 4,572 men (Black = 1,352, White = 3,192, Other Race = 28) with advanced prostate cancer (T4/M1/N1) were included.

• A decreased risk of all-cause (Hazard Ratio (HR) 0.84) and PCa-specific death (HR: 0.76) was observed in relation to post-diagnostic metformin use.

• The inverse link between post-diagnostic metformin treatment and both all-cause PCa-specific mortality was limited to White men, in the stratified analyses.

• A decreased risk of all-cause (HR: 0.75) and PCa-specific mortality (HR: 0.72) was reported in relation to post-diagnostic statin use.

• Stratified analyses revealed similar inverse links for post-diagnostic statin use and all-cause and PCa-specific mortality in both Black and White men.